| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6 (1), 1-15, 2018 | 37 | 2018 |
| Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018 | 23 | 2018 |
| Modeling Na+-Ca2+ exchange in the heart: Allosteric activation, spatial localization, sparks and excitation-contraction coupling L Chu, JL Greenstein, RL Winslow Journal of molecular and cellular cardiology 99, 174-187, 2016 | 20 | 2016 |
| Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger Frontiers in immunology 10, 924, 2019 | 13 | 2019 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 11 | 2017 |
| Quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ... CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019 | 9 | 2019 |
| Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 … T Yakovleva, V Sokolov, L Chu, W Tang, PJ Greasley, H Peilot Sjögren, ... Diabetes, Obesity and Metabolism 21 (12), 2684-2693, 2019 | 8 | 2019 |
| Na+ microdomains and sparks: Role in cardiac excitation-contraction coupling and arrhythmias in ankyrin-B deficiency L Chu, JL Greenstein, RL Winslow Journal of molecular and cellular cardiology 128, 145-157, 2019 | 6 | 2019 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 4 | 2020 |
| Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling V Sokolov, T Yakovleva, L Chu, W Tang, PJ Greasley, S Johansson, ... CPT: pharmacometrics & systems pharmacology 9 (4), 222-229, 2020 | 2 | 2020 |
| Comparison of different approaches to modeling early tumor size dynamics for accurate prediction of survival in non-small cell lung cancer (NSCLC) clinical trials Y Kosinsky, I Azarov, L Chu, G Helmlinger, K Peskov, S Aksenov Journal of Pharmacokinetics and Pharmacodynamics 45, S123-S123, 2018 | 2 | 2018 |
| Quantitative modeling as a systematic approach for drug combination evaluation in immuno-oncology (IO) G Helmlinger, Y Kosinsky, L Chu, K Peskov, V Voronova, A Borodovsky, ... Cancer Research 78 (13 Supplement), 2098-2098, 2018 | 2 | 2018 |
| Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches A Chaudhury, X Zhu, L Chu, A Goliaei, CH June, JD Kearns, AM Stein The Journal of Clinical Pharmacology 60, S147-S159, 2020 | 1 | 2020 |
| CONTRIBUTION AND REGULATION OF SGLT1 AND SGLT2 IN HEALTHY AND TYPE 2 DIABETES SUBJECTS: A DRUG-DISEASE MODELING STUDY. T Yakovleva, V Sokolov, L Chu, RC Penland, W Tang, PJ Greasley, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S51-S51, 2018 | 1 | 2018 |
| Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors L Chu, RC Penland, G Helmlinger, DW Boulton J. Pharmacokinet Pharmacodyn 44, S92, 2017 | 1 | 2017 |
| Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy. K Abdallah, B Shulgin, K Peskov, Y Kosinsky, A Vergara-Silva, ... Journal of Clinical Oncology 35 (7_suppl), 89-89, 2017 | 1 | 2017 |
| Modeling the Role of NCX in the Regulation of Cardiomyocyte Microdomain Ca2+ Dynamics L Chu, JL Greenstein, RL Winslow Biophysical Journal 110 (3), 99a, 2016 | 1 | 2016 |
| USING A SYSTEMS PHARMACOLOGY MODEL TO INVESTIGATE POTASSIUM HOMEOSTASIS IN HEALTHY AND HYPERKALEMIC SUBJECTS. G Helmlinger, L Chu, S Aksenov, R Penland, M Nagard, D Boulton CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S115-S115, 2020 | | 2020 |
| Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model K Yuri, L Chu, M Shah, K Vishwanathan, C Larsson, A Bloecher, B Willis, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | | 2019 |
| Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach G Helmlinger, I Azarov, Y Kosinsky, V Voronova, L Chu, S Mosely, ... Cancer Research 79 (13 Supplement), 1082-1082, 2019 | | 2019 |
